Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of JNJ-56136379 alone and with nucleos(t)ide analogs in chronic hepatitis B
2017-001110-29Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of bersacapavir, tenofovir disoproxil fumarate and entecavir in Chronic Hepatitis B (CHB) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Change from baseline in HBsAg levels at Week 24. Started Jan 2018; status: completed.
02
Drugs
bersacapavirtenofovir disoproxil fumarateentecavir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2017-001110-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001110-29.